Secreted phospholipase A2 as a new enzymatic trigger mechanism for localised liposomal drug release and absorption in diseased tissue

Biochimica et Biophysica Acta - Biomembranes

Volumn 1609, Issue 1, 2003, Pages 95-101

  Davidsen, Jesper ^a   Jørgensen, Kent ^b   Andresen, Thomas L ^b   Mouritsen, Ole G ^c  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b TECHNICAL UNIVERSITY OF DENMARK   (Denmark)

^c UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

Author keywords

Drug delivery; Enhancer; Fatty acid; Liposome; Lyso phospholipid; Membrane; Permeability; Phospholipase A2; Surfactant

Indexed keywords

CALCEIN; DRUG CARRIER; FATTY ACID; LIPOSOME; LYSOPHOSPHOLIPID; PHOSPHOLIPASE A2;

ARTICLE; CANCER TISSUE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG RELEASE; DRUG STABILITY; DRUG TARGETING; ENZYME ACTIVITY; HYDROLYSIS; INFLAMMATION; MALE; MEMBRANE PERMEABILITY; NONHUMAN; PRIORITY JOURNAL; RAT; SECRETION;

ANIMALS; DRUG CARRIERS; LIPOSOMES; PHARMACOKINETICS; PHOSPHOLIPASES A; TEMPERATURE;

EID: 0037427971     PISSN: 00052736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0005-2736(02)00659-4     Document Type: Article

References (39)

1. Lasic D.D., Papahadjopoulos D. Medical Applications of Liposomes. 1998;Elsevier, Amsterdam.
2. Allen T.M. Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs. 56:1998;747-756.
3. Ehrlich P. Chemotherapeutics: scientific principles, methods and results. Lancet. i:1913;445-451.
4. Blume G., Cevc G. Liposomes for the sustained drug release in vivo. Biochim. Biophys. Acta. 1029:1990;91-97.
5. Wu N.Z., Da D., Rudoll T.L., Needham D., Whorton A.R., Dewhirst M.W. Increased microvascular permeability contributes to preferential accumulation of Stealth liposomes in tumor tissue. Cancer Res. 53:1993;3765-3770.
6. Gabizon A.A., Barenholz Y. Janoff A. Liposomes: Rational Design. 1999;343-362 Marcel Dekker, New York.
7. Bakker-Woudenberg I.A.J.M., Storm G., Woodle M.C. Lasic D.D., Martin F. Stealth Liposomes. 1995;197-209 CRC Press, Boca Raton.
8. Huang S.K., Martin F.J., Friend D.S., Papahadjopoulos D. Lasic D.D., Martin F. Stealth Liposomes. 1995;119-125 CRC Press, Boca Raton.
9. Yatvin M.B., Weinstein J.N., Dennis W.H., Blumenthal R. Design of liposomes for enhanced local release of drugs by hyperthermia. Science. 202:1978;1290-1293.
10. Anyarambhatla G.R., Needham D. Enhancement of the phase transition permeability of DPPC liposomes by incorporation of MPPC: a new temperature sensitive liposome for use with mild hyperthermia. J. Liposome Res. 9:1999;491-506.
11. Meers P. Enzyme-activated targeting of liposomes. Adv. Drug Deliv. Rev. 53:2001;265-272.
12. Janssen M.J.W., Vermeulen L., Van der Helm H.A., Aarsman A.J., Slotboom A.J., Egmond M.R. Enzymatic properties of rat group IIA and V phospholipases A(2) compared. Biochim. Biophys. Acta. 1440:1999;59-72.
13. 2: its usefulness in laboratory diagnostics. Crit. Rev. Clin. Lab. Sci. 36:1999;65-163.
14. 2 in inflamed sites. Dermatologica. 179(Suppl. 1):1989;72-76.
15. 2. Biochim. Biophys. Acta. 1170:1993;217-231.
16. Saiga A., Morioka Y., Ono T., Nakano K., Ishimoto Y., Arita H., Hanasaki K. Group X secretory phospholipase A(2) induces potent productions of various lipid mediators in mouse peritoneal macrophages. Biochim. Biophys. Acta. 1530:2001;67-76.
17. 2 is increased in peritoneal and pleural effusions in patients with various types of cancer. Int. J. Cancer. 74:1997;245-250.
18. 2 messenger RNA and protein in colorectal adenomas from familial adenomatous polyposis patients. Cancer Res. 58:1998;500-503.
19. 2 activity in 9,10-dimethyl-1,2-benzanthracene-induced mammary tumors of rats. Biochim. Biophys. Acta. 617:1980;150-155.
20. 2 levels in patients with advanced cancer. Clin. Chim. Acta. 228:1994;91-99.
21. 2 activity towards lipopolymer-containing liposomes. Biochim. Biophys. Acta. 1373:1998;27-36.
22. 2 catalyzed degradation of polymer grafted PEG-liposomes: effects of lipopolymer-concentration and chain-length. Pharm. Res. 16:1999;1493-1495.
23. 2 activity. Biochemistry. 36:1997;10551-10557.
24. Schmidt A., Wolde M., Thiele C., Fest W., Kratzin H., Podtelejnikov A.V., Witke W., Huttner W.B., Soling H.D. Endophilin I mediates synaptic vesicle formation by transfer of arachidonate to lysophosphatidic acid. Nature. 401:1999;133-141.
25. Waite M. Vance D.E., Vance J. Phospholipases. 1991;269-294 Elsevier, Amsterdam.
26. 2 at 2.2 A resolution. Nature. 352:1991;79-82.
27. Hope M.J., Bally M.B., Webb G., Cullis P.R. Production of large unilamellar vesicles by a rapid extrusion procedure. Characterization of size distribution, trapped volume and ability to maintain a membrane potential. Biochim. Biophys. Acta. 812:1985;55-65.
28. 2 from peritoneal cavity of caseinate treated rat. J. Biochem. 102:1987;147-154.
29. 2. Anal. Biochem. 232:1995;7-23.
30. 2 activity and physical properties of lipid-bilayer substrates. Methods Enzymol. 286:1997;168-190.
31. Needham D., Zhelev D.V. Lysolipid exchange with lipid vesicle membranes. Ann. Biomed. Eng. 23:1995;287-298.
32. Cornell R.B., Arnold R.S. Modulation of the activities of enzymes of membrane lipid metabolism by non-bilayer-forming lipids. Chem. Phys. Lipids. 81:1996;215-227.
33. Davidsen J., Mouritsen O.G., Jørgensen K. Synergistic permeability enhancing effect of lysophospholipids and fatty acids on lipid membranes. Biochim. Biophys. Acta. 1564:2002;256-262.
34. Mouritsen O.G., Jørgensen K. A new look at lipid-membrane structure in relation to drug research. Pharm. Res. 15:1998;1507-1519.
35. Gabriel N.E., Agman N.V., Roberts M.F. Enzymatic hydrolysis of short-chain lecithin/long-chain phospholipid unilamellar vesicles: sensitivity of phospholipases to matrix phase state. Biochemistry. 26:1987;7409-7418.
36. Woodle M.C., Lasic D.D. Sterically stabilized liposomes. Biochim. Biophys. Acta. 1113:1992;171-199.
37. 2 activity and dynamic lipid bilayer microheterogeneity. Biochemistry. 35:1996;9003-9006.
38. Nielsen L.K., Bjornholm T., Mouritsen O.G. Critical phenomena - fluctuations caught in the act. Nature. 404:2000;352.
39. 2, arachidonic-acid, and eicosanoid appearance in mouse zymosan peritonitis. J. Immunol. 144:1990;2671-2677.